^
Association details:
| Biomarker: | MGMT deletion |
|---|---|
| Cancer: | Neuroendocrine Tumor |
| Drug: | temozolomide (DNA synthesis inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors
Excerpt:
MGMT deficiency, measured by immunohistochemistry, is more common in pancreatic neuroendocrine tumors than in carcinoid tumors as is treatment response to temozolomide-based therapy. Absence of MGMT may explain the sensitivity of some pancreatic neuroendocrine tumors to treatment.
DOI:
10.1158/1078-0432.CCR-08-1476
